# Omeros Corp: overview OMER · Nasdaq · CIK 1285819 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/omer.md) · [Financials](/companies/omer/financials.md) · [Filings](/companies/omer/filings.md) · [Insiders](/companies/omer/insiders.md) Latest reported revenue: [$28.5m](/filings/0001437749-26-027318.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-027318). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | [0.0](/filings/0001437749-26-016720.md) | [0.0](/filings/0001437749-26-027318.md) | not reported | not reported | [9.9](/filings/0001437749-26-016720.md) | [28.5](/filings/0001437749-26-027318.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(176.1%)](/filings/0001437749-26-016720.md) | [0.3%](/filings/0001437749-26-027318.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [566.7%](/filings/0001437749-26-027318.md) | [46.4%](/filings/0001437749-26-027318.md) | | Diluted EPS | $ per share | [(0.56)](/filings/0001437749-25-034826.md) | not reported | [(0.58)](/filings/0001437749-26-016720.md) | [(0.43)](/filings/0001437749-26-027318.md) | [(0.47)](/filings/0001437749-25-034826.md) | not reported | [0.62](/filings/0001437749-26-016720.md) | [0.15](/filings/0001437749-26-027318.md) | | Free cash flow | $m | [(32.1) d](/filings/0001437749-25-034826.md) | [(29.0) d](/filings/0001437749-26-010636.md) | [(35.9)](/filings/0001437749-26-016720.md) | [(22.0) d](/filings/0001437749-26-027318.md) | [(18.5) d](/filings/0001437749-25-034826.md) | [(39.8) d](/filings/0001437749-26-010636.md) | [(14.5)](/filings/0001437749-26-016720.md) | [4.1 d](/filings/0001437749-26-027318.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [3.12](/filings/0001558370-23-003575.md) | [0.76](/filings/0001558370-23-003575.md) | [(1.88)](/filings/0001437749-26-010636.md) | [(2.70)](/filings/0001437749-26-010636.md) | [(0.05)](/filings/0001437749-26-010636.md) | | Free cash flow | $m | [(110)](/filings/0001437749-24-010416.md) | [(86.6)](/filings/0001437749-25-010216.md) | [74.3](/filings/0001437749-26-010636.md) | [(149)](/filings/0001437749-26-010636.md) | [(116)](/filings/0001437749-26-010636.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/omer/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $57.5m | 6,044,633 | | Added +735,007 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $29.9m | 3,148,384 | | Added +807,653 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.2m | 3,072,050 | | Added +88,791 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $22.1m | 2,319,906 | | Added +400,331 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $18.2m | 1,914,460 | | Added +162,137 | | [STIFEL FINANCIAL CORP](/funds/720672.md) | 2026-06-30 | $17.5m | 1,836,925 | | Added +5,340 | | [Affinity Asset Advisors, LLC](/funds/1773195.md) | 2026-06-30 | $13.4m | 1,411,300 | Put | New +1,411,300 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $9.2m | 971,300 | Call | Added +456,200 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $9.2m | 962,828 | | Added +244,153 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $8.7m | 918,700 | Put | Added +514,700 | ## Recent filings [All 784 filings](/companies/omer/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 16:05 ET | [8-K](/filings/0001552781-26-000441.md) | 5.02 Departure or appointment of officers or directors | 0001552781-26-000441 | | 2026-08-12 | 16:12 ET | [10-Q](/filings/0001437749-26-027318.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027318 | | 2026-08-12 | 16:09 ET | [8-K](/filings/0001437749-26-027313.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027313 | | 2026-07-20 | 17:05 ET | [8-K](/filings/0001437749-26-023886.md) | 8.01 Other events | 0001437749-26-023886 | | 2026-07-06 | 08:30 ET | [8-K](/filings/0001552781-26-000377.md) | 8.01 Other events | 0001552781-26-000377 | | 2026-06-25 | 06:02 ET | [8-K](/filings/0001437749-26-021617.md) | 5.07 Shareholder vote results | 0001437749-26-021617 | | 2026-06-18 | 07:52 ET | [8-K](/filings/0001437749-26-021040.md) | 8.01 Other events | 0001437749-26-021040 | | 2026-05-13 | 16:07 ET | [10-Q](/filings/0001437749-26-016720.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016720 | | 2026-05-13 | 16:06 ET | [8-K](/filings/0001437749-26-016718.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-016718 | | 2026-04-30 | 08:00 ET | [DEF 14A](/filings/0001552781-26-000281.md) | Proxy statement, period 2026-06-18 | 0001552781-26-000281 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010636.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/f4eb3017-d1d6-428c-8258-0d9fc5dbe6a8) ## About the filer - CIK: 1285819 - Tickers: OMER - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: WA - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.